Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population

BACKGROUND: Several anti-inflammatory biologic medications are available in the United States for the treatment of moderate-to-severe rheumatoid arthritis, moderate-to-severe psoriasis, psoriatic arthritis, or ankylosing spondylitis. The tumor necrosis factor (TNF) blockers etanercept, adalimumab, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Schabert, Vernon F., Watson, Crystal, Joseph, George J., Iversen, Paige, Burudpakdee, Chakkarin, Harrison, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438048/
https://www.ncbi.nlm.nih.gov/pubmed/24074008
http://dx.doi.org/10.18553/jmcp.2013.19.8.621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438048/
https://www.ncbi.nlm.nih.gov/pubmed/24074008
http://dx.doi.org/10.18553/jmcp.2013.19.8.621

Ejemplares similares